|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0005290,
umls-concept:C0007131,
umls-concept:C0013216,
umls-concept:C0017262,
umls-concept:C0185117,
umls-concept:C0281497,
umls-concept:C0456387,
umls-concept:C0814225,
umls-concept:C0936012,
umls-concept:C1513884,
umls-concept:C1522673,
umls-concept:C2911684
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2007-2-9
|
|
pubmed:abstractText |
High class III beta-tubulin (bTubIII) expression in advanced non-small cell lung cancer is known to correlate with reduced response rates and inferior survival with anti-microtubule agents. JBR.10 showed a 12% and 15% improvement in 5-year recurrence-free survival (RFS) and overall survival (OS), respectively, with the addition of cisplatin and vinorelbine following resection of stage IB-II non-small cell lung cancer. We sought to determine the effect of bTubIII on patient outcome and benefit from adjuvant chemotherapy in the JBR.10 trial.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:Aviel-RonenSaritS,
pubmed-author:ButtsCharlesC,
pubmed-author:DabbaghLaithL,
pubmed-author:DingKeyueK,
pubmed-author:DumontetCharlesC,
pubmed-author:LaiRaymondR,
pubmed-author:MackeyJohnJ,
pubmed-author:ReimanTonyT,
pubmed-author:SèvePascalP,
pubmed-author:SeymourLesleyL,
pubmed-author:ShepherdFrances AFA,
pubmed-author:TsaoMing-SoundMS,
pubmed-author:WhiteheadMarloM,
pubmed-author:WintonTimothyT
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
13
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
994-9
|
|
pubmed:dateRevised |
2007-12-3
|
|
pubmed:meshHeading |
pubmed-meshheading:17289895-Aged,
pubmed-meshheading:17289895-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17289895-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:17289895-Chemotherapy, Adjuvant,
pubmed-meshheading:17289895-Cisplatin,
pubmed-meshheading:17289895-Disease-Free Survival,
pubmed-meshheading:17289895-Female,
pubmed-meshheading:17289895-Humans,
pubmed-meshheading:17289895-Immunohistochemistry,
pubmed-meshheading:17289895-Lung Neoplasms,
pubmed-meshheading:17289895-Male,
pubmed-meshheading:17289895-Middle Aged,
pubmed-meshheading:17289895-Prognosis,
pubmed-meshheading:17289895-Time Factors,
pubmed-meshheading:17289895-Treatment Outcome,
pubmed-meshheading:17289895-Tubulin,
pubmed-meshheading:17289895-Vinblastine
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10.
|
|
pubmed:affiliation |
Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
